The estimated Net Worth of Jane Ph D Hsiao is at least $45 millió dollars as of 17 January 2024. Jane Hsiao owns over 150,000 units of Opko Health Inc stock worth over $43,679,813 and over the last 17 years he sold OPK stock worth over $0. In addition, he makes $1,345,200 as Vice Chairman of the Board és Chief Technical Officer at Opko Health Inc.
Jane has made over 38 trades of the Opko Health Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 150,000 units of OPK stock worth $142,500 on 17 January 2024.
The largest trade he's ever made was exercising 7,732,738 units of Opko Health Inc stock on 31 January 2015 worth over $4,794,298. On average, Jane trades about 316,745 units every 78 days since 2007. As of 17 January 2024 he still owns at least 27,999,880 units of Opko Health Inc stock.
You can see the complete history of Jane Hsiao stock trades at the bottom of the page.
Dr. Jane H. Hsiao Ph.D. serves as Vice Chairman of the Board, Chief Technical Officer of the Company. Dr. Hsiao has served as Vice-Chairman and Chief Technical Officer of the Company since May 2007 and as a director since February 2007. Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, Inc. (OTC US:NIMU), a medical device company, since October 2008 and was named Interim Chief Executive Officer of Non-Invasive Monitoring Systems, Inc. in February 2012. Dr. Hsiao is also a director of each of TransEnterix, Inc. (NYSE American:TRXC), a medical device company, Neovasc, Inc. (NASDAQ CM:NVCN), a company developing and marketing medical specialty vascular devices, and Cocrystal Pharma, Inc. (NASDAQ GM:COCP). Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006. Dr. Hsiao served as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX’s veterinary products subsidiary, from 1998 to 2006.
As the Vice Chairman of the Board és Chief Technical Officer of Opko Health Inc, the total compensation of Jane Hsiao at Opko Health Inc is $1,345,200. There are 1 executives at Opko Health Inc getting paid more, with Phillip Frost having the highest compensation of $1,405,200.
Jane Hsiao is 72, he's been the Vice Chairman of the Board és Chief Technical Officer of Opko Health Inc since 2007. There are 7 older and 14 younger executives at Opko Health Inc. The oldest executive at Opko Health Inc is John Paganelli, 85, who is the Independent Director.
Jane's mailing address filed with the SEC is OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI, FL, 33137.
Over the last 18 years, insiders at Opko Health Inc have traded over $862,245 worth of Opko Health Inc stock and bought 128,867,460 units worth $425,265,065 . The most active insiders traders include Phillip Md Et Al Frost Neva..., Phillip Md Et Al Frost Gamm... és Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of $142,696. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth $127,000.
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Opko Health Inc executives and other stock owners filed with the SEC include: